当前位置: X-MOL首页最新SCI期刊查询及投稿分析系统 › ACS Infectious Diseases杂志
ACS Infectious Diseases
基本信息
期刊名称 ACS Infectious Diseases
ACS INFECT DIS
期刊ISSN 2373-8227
期刊官方网站 http://pubs.acs.org/journal/aidcbc
是否OA
出版商 American Chemical Society (ACS)
出版周期
始发年份
年文章数 161
最新影响因子 5.3(2022)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学2区 CHEMISTRY, MEDICINAL 药物化学2区
INFECTIOUS DISEASES 传染病学2区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 4.72 1.759 1.157
Medicine
Infectious Diseases
16 / 272 94%
补充信息
自引率 7.10%
H-index 8
SCI收录状况 Science Citation Index Expanded
官方审稿时间
网友分享审稿时间 数据统计中,敬请期待。
PubMed Central (PML) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2373-8227%5BISSN%5D
投稿指南
期刊投稿网址 https://acs.manuscriptcentral.com/acs
收稿范围

ACS Infectious Diseases是第一本以强调化学及其在传染病研究的多学科协作领域中作用的杂志。该期刊涵盖了与传染病研究有关的化学研究的所有方面,包括病原体、宿主-病原体相互作用、治疗、诊断、疫苗、药物递送系统以及其他与传染病有关的生物医学技术开发的研究。该期刊的编辑精通传染病的化学和生物学知识,旨在弥合这两个学科之间的鸿沟。 ACS Infectious Diseases欢迎平衡了化学与生物领域的相关稿件,并鼓励围绕特定病原体和疾病展开相关问题的讨论。 

期刊收录研究方向:病原体、宿主-病原体相互作用(利用结构生物学、化学生物学、糖生物学、物理化学、核酸化学和生物化学阐释发病机理的分子机制,剖析发病机理的工具的开发),疗法(基于靶标、表型或计算的方法,发现和开发治疗传染病的新药剂,重点在于建立作用机制,了解结合模式和抑制机制,和/或讨论病原体特异性给药物开发带来的挑战;开发新技术以促进表征、验证和确定潜在药物靶标的优先次序或评估抗感染剂细胞渗透的理化基础;药物抗性的机理研究,疫苗(合成疫苗和小分子疫苗佐剂的发现和开发;表位结合的结构、物理或计算研究),诊断(利用物理、表面、分析和纳米化学技术开发新型且改进的诊断方法;利用结构生物学、分子生物学和化学生物学研究诊断目标),药物输送系统(使用新型材料和技术,例如纳米技术,来递送抗生素)。

收录体裁
Articles
Featured Articles
Letters
Reviews
Perspectives
Viewpoints
投稿指南 https://publish.acs.org/publish/author_guidelines?coden=aidcbc
投稿模板 https://publish.acs.org/publish/author_guidelines?coden=aidcbc#document_templates_and_format
参考文献格式 https://endnote.com/downloads/styles/
编辑信息

Editor-in-Chief

Courtney C. Aldrich
Department of Medicinal Chemistry
College of Pharmacy, University of Minnesota
Editor's Office: (612) 625-7956
E-mail: eic@id.acs.org

Acquisitions Editor

Janice E. Silverman
E-mail: j_silverman@acs.org

Managing Editor

Lorraine Clark
Phone: (202) 872-6984
E-mail: l_clark@acs.org

Associate Editors

Mark Blaskovich
The University of Queensland
E-mail: blaskovich-office@id.acs.org
Felix Calderón
GlaxoSmithKline (GSK)
E-mail: calderon-office@id.acs.org
Zhiyong Lou
Tsinghua University
E-mail: lou-office@id.acs.org
Pei-Yong Shi
University of Texas Medical Branch
E-mail: shi‐office@id.acs.org
Peter Tonge
Stony Brook University
E-mail: tonge-office@id.acs.org
Gerard Wright
McMaster University
E-mail: wright-office@id.acs.org
Priscilla Yang
Harvard Medical School
E-mail: yang-office@id.acs.org


Editorial Advisory Board

Vicky M. Avery
Griffith University
Clifton E. Barry, III
NIH/NIAID
Helen Blackwell
University of Wisconsin, Madison
Patricia Bradford
Antimicrobial Development Specialists, LLC
Heike Brötz-Oesterhelt
Microbial Bioactive Compounds
Eric D. Brown
McMaster University
Lori Burrows
McMaster University
Karen Bush
Indiana University Bloomington
Erin Carlson
University of Minnesota
Kelly Chibale
University of Cape Town
Luiz Pedro Sorio de Carvalho
The Francis Crick Institute
Emily R. Derbyshire
Duke University
Thierry Tidiane Diagana
Novartis Institute for Tropical Diseases
Cynthia S. Dowd
George Washington University
Erin M. Duffy
Melinta Therapeutics, Inc.
David M. Ferguson
University of Minnesota
David A. Fidock
Columbia University Medical Center
Colin Fishwick
University of Leeds
Caren L. Freel Meyers
Johns Hopkins University
Sylvie Garneau-Tsodikova
University of Kentucky
Ian Gilbert
University of Dundee
Stanislav Gobec
University of Ljubljana
Jayanta Haldar
Jawaharlal Nehru Centre for Advanced Scientific Research
Daria J. Hazuda
Merck and Company
Anna Hirsch
University of Groningen
Deb Hung
Harvard Medical School
Julian G. Hurdle
Institute of Biosciences and Technology, Texas A&M Health Science Center
Satoshi Ichikawa
Hokkaido University
Audrey John
Washington University School of Medicine
Kimberly Kline
Nanyang Technological University
Damian Krysan
University of Iowa
Richard E. Lee
St. Jude Children's Research Hospital
Jennifer A. Leeds
Novartis Institutes for Biomedical Research
Dennis D. Liotta
Emory University
Zhenkun Ma
TenNor Therapeutics Limited
Christian C. Melander
North Carolina State University
Valerie Mizrahi
University of Cape Town
Shahriar Mobashery
University of Notre Dame
Johan Neyts
University of Leuven
Alex J. O'Neill
University of Leeds
John Pezacki
University of Ottawa
Michael Pollastri
Northeastern University
Terry D. Roemer
Merck and Company
Aileen Rubio
Spero Therapeautics
Judy A. Sakanari
University of California, San Francisco
Celia A. Schiffer
University of Massachusetts Medical School
Megan Shaw
Mount Sinai Hospital
Hong C. Shen
Roche Innovation Center Shanghai
Chunquan Sheng
Second Military Medical University
Lynn Silver
LL Silver Consulting LLC
Erick Strauss
Stellenbosch University
Ruben Tommasi
Entasis Therapeutics
Steven Townsend
Vanderbilt University
Jonathan L. Vennerstrom
University of Nebraska Medical Center
Pooja Vijayaraghavan
Amity Institute of Biotechnology
Zhengqiang Wang
University of Minnesota
Elizabeth Winzeler
University of California San Diego
Fumiaki Yokokawa
Novartis Institute for Tropical Diseases
Helen I Zgurskaya
University of Oklahoma
我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug